Administration of a non-depleting NKG2D-blocking antibody has been shown to prevent the development of disease in murine models of autoimmunity (type 1 diabetes) [21,22], transfer-induced colitis [22], and collagen-induced arthritis [12]. Here, KLRK1 is linked to colitis.